Loading…
Greenway Herbal Products LLC was cited for selling unapproved CBD products with claims to mitigate, prevent, treat, diagnose, or cure COVID-19, violating section 505(a) of the FD&C Act by marketing unapproved new drugs. The products were also misbranded under section 502 of the FD&C Act and their sale in interstate commerce violated sections 301(a) and (d). The FDA's enforcement action was issued during the COVID-19 public health emergency, when the agency prioritized protecting consumers from unauthorized products making pandemic-related health claims.